# Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00193466** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 40 (—)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** CAMPTH-1H

## Key facts

- **NCT ID:** NCT00193466
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2007-01
- **Final completion:** 2008-04
- **Target enrollment:** 40 (—)
- **Last updated:** 2010-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193466, "Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00193466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*